MedTrace Logo

Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19

NCT04351659 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2022-03-31

No results posted yet for this study

Summary

The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously for the treatment of severe SARS-CoV-2 infections.

Conditions

Interventions

OTHER

Blood donation from convalescent donor

Donation of 1 unit of blood or leukapheresis

Sponsors & Collaborators

  • Singapore General Hospital

    collaborator OTHER

  • National University Hospital, Singapore

    collaborator OTHER

  • KK Women's and Children's Hospital

    lead OTHER_GOV

Principal Investigators

  • Wing Hang Leung · KK Hospital, SingHealth, Duke-NUS

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-14
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351659 on ClinicalTrials.gov